Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
BMC Neurol ; 11: 82, 2011 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-21722376

RESUMEN

BACKGROUND: Previous studies suggest central nervous system involvement in chronic fatigue syndrome (CFS), yet there are no established diagnostic criteria. CFS may be difficult to differentiate from clinical depression. The study's objective was to determine if spectral coherence, a computational derivative of spectral analysis of the electroencephalogram (EEG), could distinguish patients with CFS from healthy control subjects and not erroneously classify depressed patients as having CFS. METHODS: This is a study, conducted in an academic medical center electroencephalography laboratory, of 632 subjects: 390 healthy normal controls, 70 patients with carefully defined CFS, 24 with major depression, and 148 with general fatigue. Aside from fatigue, all patients were medically healthy by history and examination. EEGs were obtained and spectral coherences calculated after extensive artifact removal. Principal Components Analysis identified coherence factors and corresponding factor loading patterns. Discriminant analysis determined whether spectral coherence factors could reliably discriminate CFS patients from healthy control subjects without misclassifying depression as CFS. RESULTS: Analysis of EEG coherence data from a large sample (n = 632) of patients and healthy controls identified 40 factors explaining 55.6% total variance. Factors showed highly significant group differentiation (p < .0004) identifying 89.5% of unmedicated female CFS patients and 92.4% of healthy female controls. Recursive jackknifing showed predictions were stable. A conservative 10-factor discriminant function model was subsequently applied, and also showed highly significant group discrimination (p < .001), accurately classifying 88.9% unmedicated males with CFS, and 82.4% unmedicated male healthy controls. No patient with depression was classified as having CFS. The model was less accurate (73.9%) in identifying CFS patients taking psychoactive medications. Factors involving the temporal lobes were of primary importance. CONCLUSIONS: EEG spectral coherence analysis identified unmedicated patients with CFS and healthy control subjects without misclassifying depressed patients as CFS, providing evidence that CFS patients demonstrate brain physiology that is not observed in healthy normals or patients with major depression. Studies of new CFS patients and comparison groups are required to determine the possible clinical utility of this test. The results concur with other studies finding neurological abnormalities in CFS, and implicate temporal lobe involvement in CFS pathophysiology.


Asunto(s)
Trastorno Depresivo Mayor/diagnóstico , Electroencefalografía , Síndrome de Fatiga Crónica/diagnóstico , Procesamiento de Señales Asistido por Computador , Adulto , Estudios de Casos y Controles , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis de Componente Principal
2.
J Gen Virol ; 91(Pt 4): 893-7, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20007355

RESUMEN

Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a neuro-immune disease of uncertain pathogenesis. Human parvovirus B19 infection has been shown to occur just prior to development of the onset of CFS/ME in several cases, although B19 seroprevalence studies do not show any significant differences between CFS/ME and controls. In this study, we analysed parvovirus B19 markers in CFS/ME patients (n=200), diagnosed according to Fukuda CDC criteria, and normal blood donors (n=200). Serum from each subject was tested for anti-B19 VP2 IgM and IgG (by Biotrin ELISA), anti-B19 NS1 IgM and IgG (by immunofluorescence), and B19 DNA (by real-time PCR). CFS/ME patients and normal blood donors had a similar B19 seroprevalence (75 % versus 78 %, respectively). Eighty-three CFS patients (41.5 %) as compared with fourteen (7 %) normal blood donors tested positive for anti-B19 NS1 IgG (chi(2)=64.8; P<0.0001; odds ratio=9.42, CI 5.11-17.38). Of these 83 patients, 61 complained of chronic joint pain, while 22 did not. Parvovirus B19 DNA was detected in serum of 11 CFS patients and none of the controls by Taqman real-time PCR (chi(2)=9.35, P<0.002). Positivity for anti-B19 NS1 IgG was associated with higher expression levels of the human CFS-associated genes NHLH1 and GABPA. As NS1 antibodies are thought to indicate chronic or severe courses of B19 infection, these findings suggest that although the seroprevalence of B19 in CFS patients is similar to controls, the immune control of the virus in these patients may not be efficient.


Asunto(s)
Anticuerpos Antivirales/sangre , Artralgia/inmunología , Síndrome de Fatiga Crónica/virología , Parvovirus B19 Humano/inmunología , Proteínas no Estructurales Virales/inmunología , Adulto , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/genética , Enfermedad Crónica , Síndrome de Fatiga Crónica/inmunología , Femenino , Factor de Transcripción de la Proteína de Unión a GA/genética , Humanos , Masculino
3.
J Pediatr ; 155(1): 84-9, 89.e1, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19394037

RESUMEN

OBJECTIVE: To examine the effects of high doses of extended-release methylphenidate (OROS MPH) on cardiovascular variables in adolescents with attention deficit hyperactivity disorder (ADHD). STUDY DESIGN: ECG indices plus systolic blood pressure (SBP), diastolic BP (DBP) and heart rate (HR) were assessed during an open-label study of OROS MPH in 114 adolescents with ADHD (doses up to 1.5 mg/kg/d). Cardiovascular parameters were assessed at 6 weeks and 6 months. RESULTS: Small but statistically significant changes in DBP and HR were observed at 6 weeks, without further increases up to 6 months' follow-up. A small but statistically significant increase in SBP was observed over time. Twenty-nine percent of patients had isolated elevations in BP readings prior to study entry, and 14% had >3 consecutive visits at which elevated BP were observed during OROS MPH treatment. No clinically significant changes in ECG parameters were observed. No serious cardiovascular adverse events occurred. CONCLUSIONS: Treatment with relatively high doses of OROS MPH was associated with small but statistically significant mean increases in BP and HR, primarily during the first 6 weeks of treatment, without clinically meaningful changes in ECG. These observations are consistent with previous reports using lower doses.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico , Presión Sanguínea/efectos de los fármacos , Estimulantes del Sistema Nervioso Central/efectos adversos , Frecuencia Cardíaca/efectos de los fármacos , Metilfenidato/efectos adversos , Adolescente , Estimulantes del Sistema Nervioso Central/administración & dosificación , Niño , Preparaciones de Acción Retardada , Diástole/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Electrocardiografía , Femenino , Estudios de Seguimiento , Humanos , Masculino , Metilfenidato/administración & dosificación , Estudios Prospectivos , Sístole/efectos de los fármacos
4.
J Am Acad Child Adolesc Psychiatry ; 47(4): 426-434, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18388760

RESUMEN

OBJECTIVE: The main aim of this study was to evaluate the association between attention-deficit/hyperactivity disorder (ADHD) and major depression (MD) in adolescent and young adult females. METHOD: Subjects were females with (n = 140) and without (n = 122) ADHD ascertained from pediatric and psychiatric settings. Subjects were followed prospectively for 5 years into adolescence and young adulthood and reassessed in multiple nonoverlapping domains including psychiatric, cognitive, interpersonal, family, and educational functioning. RESULTS: Females with ADHD had a 2.5 times higher risk for MD at adolescent follow-up compared with control females, adjusting for psychiatric comorbidity. MD in females with ADHD was associated with an earlier age at onset, greater than twice the duration, more severe depression-associated impairment, a higher rate of suicidality, and a greater likelihood of requiring psychiatric hospitalization than MD in control girls. Parental MD and proband mania were significant predictors of MD among females with ADHD, independently of other predictors. CONCLUSIONS: MD emerging in the context of ADHD in females is an impairing and severe comorbidity worthy of further clinical and scientific considerations.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad/epidemiología , Trastorno Depresivo Mayor/epidemiología , Adolescente , Adulto , Edad de Inicio , Trastorno por Déficit de Atención con Hiperactividad/diagnóstico , Trastorno por Déficit de Atención con Hiperactividad/genética , Trastorno por Déficit de Atención con Hiperactividad/psicología , Trastorno Bipolar/diagnóstico , Trastorno Bipolar/epidemiología , Trastorno Bipolar/genética , Trastorno Bipolar/psicología , Estudios de Casos y Controles , Comorbilidad , Trastorno Depresivo Mayor/diagnóstico , Trastorno Depresivo Mayor/genética , Trastorno Depresivo Mayor/psicología , Femenino , Estudios de Seguimiento , Predisposición Genética a la Enfermedad/genética , Hospitalización/estadística & datos numéricos , Humanos , Fenotipo , Embarazo , Embarazo en Adolescencia/psicología , Embarazo en Adolescencia/estadística & datos numéricos , Factores de Riesgo , Medio Social , Intento de Suicidio/prevención & control , Intento de Suicidio/psicología , Intento de Suicidio/estadística & datos numéricos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA